MINI FUTURE LONG - NOVO-NORDISK B | Real-time Euronext Paris 13:38:45 03/06/2024 BST | ||
| 11.12 EUR | -2.33% |
|
| 1 month | +7.71% | ||
| 3 months | +30.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 11.12 | -2.33% |
| 31/05/24 | 11.38 | +1.20% |
| 30/05/24 | 11.24 | +1.17% |
| 29/05/24 | 11.12 | -1.07% |
| 28/05/24 | 11.24 | -0.84% |
Real-time Euronext Paris
Last update June 03, 2024 at 01:38 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| I35LB | |
| ISIN | FRBNPP05WT99 |
| Date issued | 10/08/2023 |
| Strike | 504.5 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 4.03 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.84 € |
|---|---|
| Lowest since issue | 3.565 € |
| Spread | 0.01 € |
| Spread % | 0.09% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- I35LB Certificat
